George Lau

Professor George Lau graduated from The Faculty of Medicine, The University of Hong Kong in 1987. In 1992, he was awarded Hong Kong-Stanford scholarship for his further training in Gastroenterology and Hepatology at the Stanford University, USA. In 1998, he was recommended by Professor Roger Williams to be further trained in translational Hepatology at the Institute of Hepatology, University College of London (supported by the Royal Society Award). In 2002, he was promoted to Senior Lecturer and Consultant in Gastroenterology and Hepatology at Queen Mary Hospital, Hong Kong. In 2006, he was promoted to full Clinical Professor and assistant Dean, Faculty of Medicine, The University of Hong Kong. He was also well respected by his peer in academic Hepatology and was elected as 19th President of The Asian Pacific Association for the Study of the Liver (APASL) in 2008. In 2009, he founded and become Chairman and Consultant in Gastroenterology and Hepatology, Humanity and Health Medical Group, Hong Kong. Concurrently, he was appointed as the Co-director and Chair Professor at Liver disease and Transplant Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China, Chair Professor at Zhongshan Hospital, Fudan University, Shanghai, China, Distinguished Professor at Shulan International Medical College, Hangzhou, Zhejiang Province, China, Visiting Professor at Qingdao University, Shandong Province, China and Chief Scientist of Lishui Municipal Central Hospital, Zhejiang Province, China. Prof. Lau’s research interest is immunotherapy in liver diseases. Throughout his 3 decades of research, he has published over >300 original articles (including NEJM, Lancet, J Hepatol, Hepatology and Hepatology International) with a citation of 45,000+ and a H-index of 96. Notably, Dr Lau is the lead author for the phase 3 pegylated interferon for CHB in 2005 and HIMALAYA study for HCC in 2022. Prof. Lau has received many awards and honors, including Ten Most Outstanding Young Persons 2002 (HKSAR), HKU Medical Faculty Outstanding Research Output Award, National Science and Technology Progress Award (State Science and Technology Prizes) – Technological advancement in Chronic hepatitis B infection management, Hong Kong SAR Chief Executive’s Commendation for government service, and APASL Okuda-Omata Distinguished Award. Currently, he is the senior member of steering committee of APASL, chairman of APASL Viral Elimination Task Force, and Co-Chairman of APASL Oncology Guideline, Program Director of APASL Hepatology Webinar, Faculty Member of APASL School of Hepatology, Convenor of “Highlight of Hepatology International” Webinar, and executive governance board member of The Asian-Pacific Digestive Disease Federation (APDWF).